Related references
Note: Only part of the references are listed.Sintilimab plus oxaliplatin/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)/esophagogastric junction (GEJ) adenocarcinoma
Jiang Haiping et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma.
Ying Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer
Birendra Kumar Sah et al.
NATURE COMMUNICATIONS (2020)
Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
N. Li et al.
ANNALS OF ONCOLOGY (2020)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer A Randomized Clinical Trial
Ziyu Li et al.
JAMA SURGERY (2019)
LBA42Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial)
J Ji et al.
ANNALS OF ONCOLOGY (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis
Ziyu Li et al.
PLOS ONE (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
The 8th edition of the AJCC Cancer Staging Manual. Updates in otorhinolaryngology, head and neck surgery
J. Doescher et al.
HNO (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
Kohei Shitara et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET ONCOLOGY (2016)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas A Summary of 480 Cases
Karen Becker et al.
ANNALS OF SURGERY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
D Dindo et al.
ANNALS OF SURGERY (2004)
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
K Becker et al.
CANCER (2003)
Share Paper
